prikaz prve stranice dokumenta Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events
  Download
PDF 1.13 MB
Scientific paper - Original scientific paper
Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events
The American Journal of Emergency Medicine, 70 (2023); 41-45. https://doi.org/10.1016/j.ajem.2023.05.007
Lucijanić, Marko; Bistrović, Petra; Jordan, Ana; Mihaljević, Iva; Bukvić, Stela; Kovačević, Stjepan; Ranilović, Darjan; Sakota, Sara; Vlasac Glasnović, Josipa; Delić-Brkljačić, Diana

Cite this document

Lucijanić, M., Bistrović, P., Jordan, A., Mihaljević, I., Bukvić, S., Kovačević, S. ... Delić Brkljačić, D. (2023). Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events. The American Journal of Emergency Medicine, 70., 41-45. doi: 10.1016/j.ajem.2023.05.007

Lucijanić, Marko, et al. "Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events." The American Journal of Emergency Medicine, vol. 70, 2023, pp. 41-45. https://doi.org/10.1016/j.ajem.2023.05.007

Lucijanić, Marko, Petra Bistrović, Ana Jordan, Iva Mihaljević, Stela Bukvić, Stjepan Kovačević, Darjan Ranilović, Sara Sakota, Josipa Vlasac Glasnović and Diana Delić Brkljačić. "Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events." The American Journal of Emergency Medicine 70 (2023): 41-45. https://doi.org/10.1016/j.ajem.2023.05.007

Lucijanić, M., et al. (2023) 'Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events', The American Journal of Emergency Medicine, 70, pp. 41-45. doi: 10.1016/j.ajem.2023.05.007

Lucijanić M, Bistrović P, Jordan A, Mihaljević I, Bukvić S, Kovačević S, and sur.. Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events. The American Journal of Emergency Medicine [Internet]. 2023 August [cited 2024 December 20];70:41-45. doi: 10.1016/j.ajem.2023.05.007

M. Lucijanić, et al., "Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events", The American Journal of Emergency Medicine, vol. 70, pp. 41-45, August 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:923043. [Accessed: 20 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events
AuthorMarko Lucijanić
AuthorPetra Bistrović
AuthorAna Jordan
AuthorIva Mihaljević
AuthorStela Bukvić
AuthorStjepan Kovačević
AuthorDarjan Ranilović
AuthorSara Sakota
AuthorJosipa Vlasac Glasnović
AuthorDiana Delić-Brkljačić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Introduction: Venous thromboembolism (VTE) and arterial thrombotic (AT) events are a striking feature of severe COVID-19, however, relationship of remdesivir use and the risk of thrombotic events is unknown and has not been investigated before. Methods: We retrospectively analyzed a cohort of 876 consecutive hospitalized severe and critical COVID-19 patients who were treated with remdesivir and compared them to 876 case-matched control patients. All patients were treated in our tertiary-level institution in period from 10/2020 to 6/2021. VTE and AT were diagnosed by objective imaging and laboratory methods. Results: After exclusion of 71 VTE and 37 AT events present at the time of hospital admission, there were a total of 70 VTE (35 in the remdesivir and 35 in the control group) and 38 AT events occurring during hospitalization (13 in the remdesivir and 25 in the control group). There was a similar cumulative post-admission VTE incidence among both remdesivir and matched control patients (P = 0.287). Significantly lower cumulative post-admission AT incidence was observed among patients treated with remdesivir than among matched control patients (1.7% vs 3.3%, HR = 0.51, P = 0.035). Tendency for lower AT rates was evident in subgroups of patients stratified according to the type of AT, as well as according to the intensity of required oxygen supplementation at the time of remdesivir use. Conclusion: Remdesivir use in severe and critical COVID-19 patients might be associated with lower occurrence of AT during hospitalization, whereas similar rates of VTE events were observed among both patients treated with remdesivir and control patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleThe American Journal of Emergency Medicine
Numberingvol. 70, pp. 41-45
p-ISSN0735-6757
DOIhttps://doi.org/10.1016/j.ajem.2023.05.007
URN:NBNurn:nbn:hr:105:923043
Publication2023-08
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0735675723002516
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2023-10-06 08:16:54